Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Kidney transplant recipients are at elevated risk for cardiovascular events and progression of chronic kidney disease (CKD). Finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, has demonstrated benefits in patients with CKD and heart failure. However, its safety and efficacy in the transplant population remain insufficiently studied. This study aims to evaluate the clinical outcomes associated with finerenone use in kidney transplant recipients.
A retrospective study was conducted in Al Ain City over a two-year period (October 2023 to 2025). Adult kidney transplant recipients receiving finerenone were included. Data collected included demographics, renal function parameters, adverse events, cardiovascular outcomes, and incidence of acute rejection. Descriptive statistical analysis was performed.
Six kidney transplant recipients were identified, with a mean age of 64 years and a female-to-male ratio of 1:1. All allografts were from living donors, with a mean post-transplant duration of 15.3 years. Baseline kidney function ranged from CKD stage I to IIIb (lowest eGFR: 42 mL/min), and all patients were maintained on triple immunosuppressive therapy.
Comorbidities included hypertension (71.4%), diabetes mellitus (71.4%), and ischemic heart disease (28.5%). Prior to finerenone initiation, renal-protective agents included ARBs (n=2), SGLT2 inhibitors (n=4), and GLP-1 receptor agonists (n=1). Baseline mean serum creatinine was 102.9 µmol/L, mean eGFR was 65.1 mL/min, and mean serum potassium was 4.05 mmol/L. Proteinuria was present, with a mean albumin-to-creatinine ratio of 20 mg/mmol. At 3 months post-initiation, renal function remained stable (mean creatinine: 105.4 µmol/L; eGFR: 63.3 mL/min; potassium: 4.34 mmol/L). At 6 months, mean creatinine was 108.9 µmol/L, eGFR was 61 mL/min, and potassium was 4.46 mmol/L. Proteinuria monitoring was inconsistent across patients.
Five patients were on tacrolimus, with mean trough levels increasing from 4.62 ng/mL at baseline to 6.2 ng/mL at 6 months and 8.2 ng/mL at 9 months. No cardiovascular events were reported during the one-year follow-up, and blood pressure remained stable. Two patients (33.3%) developed AKI (stage I–II) with hyperkalemia, attributed to NSAID use or infection.
Finerenone appears to be a safe and potentially beneficial therapeutic option in kidney transplant recipients, with stable renal function and no cardiovascular events observed during follow-up. However, close monitoring of renal function, serum potassium, and tacrolimus levels is essential. Larger, long-term studies are needed to better define the role of finerenone in this unique patient population.
